Lundbeck Sees No Demand Slowdown Amid Drug Growth

H. Lundbeck's CEO, Charl van Zyl, has expressed confidence that there is no slowdown in demand for the company's primary growth drivers, the migraine-preventing infusion Vyepti and the antipsychotic pill Rexulti. This assurance comes as the Danish pharmaceutical company maintained its full-year financial forecasts, even after reporting second-quarter sales that exceeded expectations.

Lundbeck anticipates revenue growth between 7% and 9% at constant exchange rates for the current year. Adjusted core earnings are projected to increase significantly, between 8% and 14%. These forecasts reflect positive factors from the first half of the year, though some, like a planned inventory build-up, are not expected to recur.

The company is strategically expanding its focus beyond psychiatry and migraine into the field of rare neurological diseases. This diversification strategy aims to leverage cash flow from existing successful brands to finance future developments and growth initiatives.

Despite the positive outlook, Lundbeck is preparing for the introduction of generic versions of its schizophrenia drug, Abilify Maintena, which are expected to enter markets, particularly Australia and Canada, during the second half of the year. Management believes this period of potential generic competition will be manageable and does not foresee a necessity for acquisitions to bridge any anticipated growth gap before new pipeline drugs become available.